EGFR and non-small cell lung carcinoma: A few studies have pointed out that EGFR mutation status might be able to influence the choice of PORT, especially for postoperative EGFR wild-type N2 NSCLC patients (63, 64), whose biggest problem lies in the fact that they are not entitled to the benefits of targeted drugs but might be able to obtain survival prolongation by PORT.